201 related articles for article (PubMed ID: 32722224)
1. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.
Odagiri N; Hai H; Thuy LTT; Dong MP; Suoh M; Kotani K; Hagihara A; Uchida-Kobayashi S; Tamori A; Enomoto M; Kawada N
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722224
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis.
Li W; Xia Y; Yang J; Guo H; Sun G; Sanyal AJ; Shah VH; Lou Y; Zheng X; Chalasani N; Yu Q
Hepatol Commun; 2020 Apr; 4(4):588-605. PubMed ID: 32258953
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma.
Dong MP; Enomoto M; Thuy LTT; Hai H; Hieu VN; Hoang DV; Iida-Ueno A; Odagiri N; Amano-Teranishi Y; Hagihara A; Fujii H; Uchida-Kobayashi S; Tamori A; Kawada N
Sci Rep; 2020 Feb; 10(1):3392. PubMed ID: 32099055
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer.
Liu C; Wang P; Sun Y; Dou X; Hu X; Zou W; Sun Y; Hu Q; Yue J
Front Oncol; 2022; 12():756811. PubMed ID: 35530332
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer.
Liu C; Li X; Li A; Zou W; Huang R; Hu X; Yu J; Zhang X; Yue J
J Immunol Res; 2022; 2022():9621466. PubMed ID: 35419462
[TBL] [Abstract][Full Text] [Related]
6. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients.
Xiaochen M; Xiangyang S; Fubo X; Wencheng J; Qingliang W; Yang X; Caixia L; Kai Z
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e515-e523. PubMed ID: 35289092
[TBL] [Abstract][Full Text] [Related]
7. Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization.
Ma XL; Qu XD; Yang WJ; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Pan BS; Zhou J; Fan J; Yang XR; Guo W
Clin Chim Acta; 2020 Dec; 511():67-74. PubMed ID: 32979338
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impacts of soluble immune checkpoint regulators and cytokines in patients with SARS-CoV-2 infection.
Lee N; Jeong S; Jeon K; Park MJ; Song W
Front Immunol; 2022; 13():903419. PubMed ID: 36045684
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Drug-Eluting Beads Transarterial Chemoembolization on Serum Levels of Soluble Programmed Cell Death Protein-1 in Advanced Hepatocellular Carcinoma Patients.
Ma X; Sun X; Xie F; Jian W; Wang Q; Xie Y; Li C; Zhang K
J Hepatocell Carcinoma; 2024; 11():619-628. PubMed ID: 38559553
[TBL] [Abstract][Full Text] [Related]
10. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Tampaki M; Ionas E; Hadziyannis E; Deutsch M; Malagari K; Koskinas J
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31952209
[TBL] [Abstract][Full Text] [Related]
11. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature.
Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Morishita A; Kobara H; Masaki T
Mol Clin Oncol; 2021 Aug; 15(2):154. PubMed ID: 34178325
[TBL] [Abstract][Full Text] [Related]
12. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients.
Fadriquela A; Kim CS; Lee KJ; Kang SH; Kim MY; Lee JH
J Clin Pathol; 2021 Dec; 74(12):780-786. PubMed ID: 34016716
[TBL] [Abstract][Full Text] [Related]
13. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
Leone P; Solimando AG; Fasano R; Argentiero A; Malerba E; Buonavoglia A; Lupo LG; De Re V; Silvestris N; Racanelli V
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065489
[TBL] [Abstract][Full Text] [Related]
15. Characterization of multiple soluble immune checkpoints in individuals with different Mycobacterium tuberculosis infection status and dynamic changes during anti-tuberculosis treatment.
Chen H; Zhou J; Zhao X; Liu Q; Shao L; Zhu Y; Ou Q
BMC Infect Dis; 2022 Jun; 22(1):543. PubMed ID: 35701741
[TBL] [Abstract][Full Text] [Related]
16. Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization.
Endo K; Kuroda H; Abe T; Sato H; Kooka Y; Oikawa T; Sato A; Nishiya M; Sugai T; Takikawa Y
Hepatol Res; 2021 Oct; 51(10):1082-1086. PubMed ID: 33982336
[TBL] [Abstract][Full Text] [Related]
17. Plasma Phage Load is Positively Related to the Immune Checkpoints in Patients Living with Human Immunodeficiency Virus.
Huang KZ; Ye H; Fang YY; Li T; Pei SJ; Wu LP; Su FF; Zheng XQ
Curr HIV Res; 2022; 20(4):301-308. PubMed ID: 35786189
[TBL] [Abstract][Full Text] [Related]
18. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond.
Kudo M
World J Gastroenterol; 2019 Feb; 25(7):789-807. PubMed ID: 30809080
[TBL] [Abstract][Full Text] [Related]
19. Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.
Imai N; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Hirooka Y; Goto H
World J Hepatol; 2014 Dec; 6(12):844-50. PubMed ID: 25544871
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical study for antitumor mechanism of lenvatinib and clinical studies for hepatocellular carcinoma].
Watanabe T; Koyama N
Nihon Yakurigaku Zasshi; 2019; 153(5):242-248. PubMed ID: 31092758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
